Contemporary Oncology最新文献_第8页

Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience 185例who定义的原发性血小板增多症患者的血栓风险评估:单中心经验

Contemporary Oncology Pub Date : 2015-09-16 DOI: 10.5114/wo.2015.54083

R. Dambrauskienė, R. Gerbutavičius, E. Juozaitytė, R. Gerbutavičienė

引用次数: 1

Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study 尿嘧啶/替加氟作为化疗难治性结直肠癌患者可能的补救性治疗:一项单一机构回顾性研究

Contemporary Oncology Pub Date : 2015-08-13 DOI: 10.5114/wo.2015.53374

I. V. Bayoglu, I. Yıldız, U. Varol, S. Çokmert, A. Alacacıoğlu, Y. Kucukzeybek, M. Akyol, L. Demir, A. Dirican, O. Tarhan

{"title":"Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study","authors":"I. V. Bayoglu, I. Yıldız, U. Varol, S. Çokmert, A. Alacacıoğlu, Y. Kucukzeybek, M. Akyol, L. Demir, A. Dirican, O. Tarhan","doi":"10.5114/wo.2015.53374","DOIUrl":"https://doi.org/10.5114/wo.2015.53374","url":null,"abstract":"Aim of the study Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents. Material and methods This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/m2 d1–5 in combination with leucovorin 90 mg/day, d1–5 followed by two days’ rest. Results The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2–24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6–4.6 months) and overall survival was 6.6 months (95% CI, 4.5–8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions. Conclusions This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"66 1","pages":"385 - 390"},"PeriodicalIF":0.0,"publicationDate":"2015-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87654503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The effect of Lactobacillus casei extract on cervical cancer cell lines 干酪乳杆菌提取物对宫颈癌细胞系的影响

Contemporary Oncology Pub Date : 2015-08-13 DOI: 10.5114/wo.2014.45292

Soo‐Nyung Kim, Won Moo Lee, Kyoung Sik Park, Jong Bin Kim, D. Han, J. Bae

{"title":"The effect of Lactobacillus casei extract on cervical cancer cell lines","authors":"Soo‐Nyung Kim, Won Moo Lee, Kyoung Sik Park, Jong Bin Kim, D. Han, J. Bae","doi":"10.5114/wo.2014.45292","DOIUrl":"https://doi.org/10.5114/wo.2014.45292","url":null,"abstract":"Aim of the study Lactobacillus casei (L. casei) has been shown to inhibit the proliferation of several types of cancer in vivo, but its effect on cervical cells has not been reported. We incubated cells of the human cervical cell lines Caski and HeLa with extracts of L. casei and investigated its effects on the growth of the cells and possible synergy with anticancer drugs. Material and methods Cell-free extracts of L. casei were prepared and purified. Cultures of Caski and HeLa cells adhering to tissue culture plates were treated with L. casei extract. The effects of L. casei extract on the growth of cancer cells and its possible synergy with anti-cancer drugs in cervical cancer cell lines were investigated. The cells were treated with L. casei extract alone, anti-cancer drugs alone [doxorubicin, paclitaxel, 5-fluorouracil (5-FU), and cisplatin], or L. casei extract plus anti-cancer drugs. Results L. casei extract had no significant effect on the growth rate of the two cell lines. Anti-cancer drugs alone induced growth inhibition, but there was no synergistic effect of L. casei extract on growth inhibition. Conclusions L. casei extract does not have a potent effect on the viability of cervical cancer cells in vitro. In addition, L. casei extract has no synergistic effect on the inhibition of growth of cancer cells in the presence of anti-cancer drugs.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"87 1","pages":"306 - 312"},"PeriodicalIF":0.0,"publicationDate":"2015-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83446056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Malignant transformation of calcifying cystic odontogenic tumour – a review of literature 钙化囊性牙源性肿瘤的恶性转化-文献综述

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.52654

B. Tarakji, Nipun Ashok, Ibrahim N. Alzoghaibi, M. A. Altamimi, S. Azzeghaiby, K. Baroudi, M. Nassani

引用次数: 15

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine ERCC1和RRM1作为顺铂和/或吉西他滨治疗的非小细胞肺癌、卵巢癌或胰腺癌的预测参数

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.52656

M. Ulker, B. Duman, B. Şahin, D. Gumurdulu

{"title":"ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine","authors":"M. Ulker, B. Duman, B. Şahin, D. Gumurdulu","doi":"10.5114/wo.2015.52656","DOIUrl":"https://doi.org/10.5114/wo.2015.52656","url":null,"abstract":"Background We aimed to investigate the impact of RRM1 and ERCC1 expression on response to cisplatin and/or gemcitabine chemotherapy in patients with lung, ovarian or pancreatic cancer. Material and methods Patients with lung, ovarian or pancreatic cancer, who used cisplatin and/or gemcitabine therapy were included; hospital files were examined and RRM1 and ERCC1 expression were evaluated with an immunohistochemical method on tissue cross sections from paraffin blocks of the tumour. Results Out of 89 patients, 51%, 30% and 19% had lung, ovarian and pancreatic cancer, respectively. The response rates to the therapy in patients with lung and ovarian cancer having low ERCC1 expression were 62% and 90%, respectively (p = 0.028 and p = 0.044, respectively). No significant association was found between ERCC1 expression and response to therapy in patients with pancreatic cancer (p = 0.354). Therapeutic response rates in patients with lung and pancreatic cancer with low RRM1 expression were 60% and 82%, respectively. Survival rates were higher in patients with lung cancer in which ERCC1 and RRM1 expressions were low. Median survival duration in patients with ovarian cancer showing low ERCC1 and RRM1 expressions was longer than that seen in patients with high expressions. Although no significant correlation was found between ERCC1 and the survival in ovarian cancer (p = 0.183), there was a significant correlation between RRM1 expression and survival in patients with pancreatic cancer (p = 0.005). Conclusions Our results suggest a predictive value of ERCC1 in lung and ovarian cancers, and also RRM1 in lung and pancreatic cancers.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"207 - 213"},"PeriodicalIF":0.0,"publicationDate":"2015-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90916421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Paratesticular rhabdomyosarcoma of a young adult 青年人睾丸旁横纹肌肉瘤

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.52661

Gorana Matovina-Brko, B. Nikolin, L. Popović, Z. Nikin, S. Popović-Petrović, D. Jovanović

引用次数: 2

The role of Reg IV in colorectal cancer, as a potential therapeutic target Reg IV在结直肠癌中的作用，作为潜在的治疗靶点

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.54385

Yiwang Hu, Chi Pan, Ji-yi Hu, Su-zhan Zhang

{"title":"The role of Reg IV in colorectal cancer, as a potential therapeutic target","authors":"Yiwang Hu, Chi Pan, Ji-yi Hu, Su-zhan Zhang","doi":"10.5114/wo.2015.54385","DOIUrl":"https://doi.org/10.5114/wo.2015.54385","url":null,"abstract":"Regenerating islet-derived family, member 4 (Reg IV), a member of the Reg gene family, has been reported to be overexpressed in gastrointestinal tract cancers. Reg IV overexpression in tumor cells has been associated with carcinogenesis, tissue regeneration, proliferation and resistance to apoptosis. Reg IV activates the epidermal growth factor receptor (EGFR) signaling pathway in colon cancer and increases expression of B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl), which are associated with the inhibition of apoptosis, results in mitogenic signaling in colon cancer cells, increase cell proliferation, metastasis and decreased apoptosis. Reg IV treatment inhibits 5-fluorouracil induced apoptosis, at least two mechanisms are involved in inhibition of apoptosis by Reg IV, including Bcl-2 and dihydropyrimidine dehydrogenase (DPD). These studies may lead to novel therapeutic strategies for cancers expressing Reg IV. Recently, one proteoglycan was confirmed to disrupt this signaling pathway to perform antitumor effect. This review summaries current knowledge of the expression and roles of Reg IV in human colorectal cancer, describes the possible signaling pathway which Reg IV activates, and discusses the relevance of Reg IV as a potential therapeutic target for cancer treatment.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"71 1","pages":"261 - 264"},"PeriodicalIF":0.0,"publicationDate":"2015-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83925302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma – Preliminary study 喉癌中Th17细胞群调节细胞因子表达的初步研究

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.51612

Renata Kopta, M. Mochocki, P. Morawski, E. Brzezińska‐Błaszczyk, I. Lewy-Trenda, K. Starska

{"title":"Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma – Preliminary study","authors":"Renata Kopta, M. Mochocki, P. Morawski, E. Brzezińska‐Błaszczyk, I. Lewy-Trenda, K. Starska","doi":"10.5114/wo.2015.51612","DOIUrl":"https://doi.org/10.5114/wo.2015.51612","url":null,"abstract":"Aim of the study Aim of the study was to evaluate the potential role of regulatory and proinflammatory cytokines IL-23 and IL-17 as Th17 lymphocyte activity markers in relation to invasiveness in laryngeal cancer. Material and methods The immunological analysis was conducted in 50 patients treated for squamous cell laryngeal carcinoma and 30 healthy volunteers as controls. The levels of IL-23 and IL-17 in supernatants of purified peripheral blood mononuclear cell cultures were determined by using the enzyme-linked immunosorbent assay (ELISA). The clinicomorphological criteria included pTNM, stage, G, and the total tumour front grading (TFG) score. Results Our data demonstrated higher concentrations of IL-23 in patients as compared to controls (p = 0.0001). No statistical difference for IL-17 in these groups was observed. Our study revealed significant dependences in IL-23 expression on pT (p = 0.04), histological differentiation (p = 0.04), and TFG total score (p = 0.02). Advanced tumours (pT3–pT4) with higher grade (G2–G3) and higher invasiveness (> 14 TFG points) were characterised by elevated IL-23 levels in PBMC supernatants. Our data did not indicate a relationship between cytokine levels and three- and five-year survival. However, a tendency towards lower content of IL-23 in PBMC cultures in patients who lived longer than five years after treatment was noted. The relationships between IL-17 level in PBMC cultures and clinicomorphological and prognostic parameters have not been disclosed. Conclusions The results of this study suggest the importance of regulatory cytokine IL-23 in determining the aggressive potential of laryngeal carcinomas.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"10 1","pages":"195 - 200"},"PeriodicalIF":0.0,"publicationDate":"2015-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85039375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Use of high-dose oxycodone hydrochloride in patients with visceral and neuropathic pain 大剂量盐酸羟考酮在内脏和神经性疼痛患者中的应用

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.52662

J. Kucharz, Iwona Filipczak-Bryniarska, A. Michałowska-Kaczmarczyk, R. Herman, K. Krzemieniecki

引用次数: 8

Osteosarcoma of the larynx 喉骨肉瘤

Contemporary Oncology Pub Date : 2015-07-08 DOI: 10.5114/wo.2015.52659

Piotr Sawicki, W. Każmierczak, Łukasz Szylberg, A. Marszałek

{"title":"Osteosarcoma of the larynx","authors":"Piotr Sawicki, W. Każmierczak, Łukasz Szylberg, A. Marszałek","doi":"10.5114/wo.2015.52659","DOIUrl":"https://doi.org/10.5114/wo.2015.52659","url":null,"abstract":"Malignant neoplasms of the larynx are divided into epithelial and non-epithelial. Non-epithelial neoplasms include, among others, mesenchymal chondrosarcomas and osteosarcomas. Few cases of laryngeal osteosarcomas described in the literature were usually treated by surgery without the need to use adjuvant radio- or chemotherapy. Few authors propose the initial application of radiotherapy or high-dose chemotherapy. Our study presents a very rare case of a woman treated due to laryngeal osteosarcoma. We have also presented diagnostic difficulties preceding a decision to perform radical surgery. The patient had been eligible for radical surgical treatment, even though there were no features of malignancy in a histopathological examination of the biopsy material. Complete laryngectomy was carried out without the surgery of the cervical lymphatic system. Laryngeal osteosarcoma was diagnosed based on the postoperative histopathological examination using vimentin and Ki67. The patient remains under the care of the Otolaryngology and Laryngological Oncology Department and Oncology Centre in Bydgoszcz. There were no reports on local recurrence or distant metastases during regular check-ups.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"59 1","pages":"246 - 249"},"PeriodicalIF":0.0,"publicationDate":"2015-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75308335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10